Stroke Management - Best Care Guide
This Active Learning Module (ALM) incorporates three topics areas:
• TIA and early assessment
• Antiplatelet therapy for secondary stroke prevention
• Preventing fatal and disabling stroke in patients with atrial fibrillation
Each topic uses a case based approach to discuss current clinical evidence and guideline recommendations. The ALM includes discussion on early assessment, risk stratification, use of risk stratification tools, secondary prevention, anticoagulants and Antiplatelet therapy and management of patients. The ALM highlights the GPs role in providing continuity of care in complex patients with multiple morbidities.
Each topic runs for 1.5 hours
To qualify for this ALM (category 1 - 40 points) participants must attend all 3 topics as well as complete the activity that will be provided.
Each participant will be provided with five PENCAT recipe cards for your practice. These PENCAT recipe cards are meant to be used for appropriate prescribing of antiplatelet, cholesterol lowering and antihypertensive therapies, using a GP management plan for stroke patients, and referring stroke patients to join peer support groups
1.TIA and early assessment
The module is case based and presents information on current clinical evidence and guideline recommendations including:
• the risk of stroke following TIA
• the signs and symptoms of TIA
• the risk of recurrent stroke after TIA
• the use of the ABCD2 tool to stratify risk of stroke
• transfer to an appropriate healthcare facility
• appropriate secondary prevention strategies in patients with TIA
• barriers to optimal stroke care
Developed and Supported by National Stroke Foundation
^To qualify for this ALM, you must attend all 3 topics and complete a post conference activity that will be supplied onsite.
2. Antiplatelet therapy for secondary stroke prevention
The module is case based and presents information on current clinical evidence and guideline recommendations including:
• expert consultation
• the use of Antiplatelet agents in stroke patients
• data from landmark clinical trails on commonly prescribed antiplatelet agents
• detailed discussion on the different antiplatelet agents
• the differences and similarities between antiplatelet agents
• the GPs role in long-term management of stroke survivors
• managing other risk factors and co-morbidities
Developed and Supported by National Stroke Foundation
^To qualify for this ALM, you must attend all 3 topics and complete a post conference activity that will be supplied onsite.
3. Preventing fatal and disabling stroke in patients with atrial fibrillation
The module presents information on:
• stroke risk and outcomes with non-valvular atrial fibrillation (NVAF)
• CHADS2 score and risk of stroke
• evidence-based use and choice of antithrombotic treatments in NVAF
• common barriers to stroke risk reduction in NVAF
• strategies to overcome barriers in the management of NVAF
• quality control of anticoagulation in atrial fibrillation
• management on warfarin, INR and bleeding risk
• GP survey and BAFTA study
Developed and Supported by National Stroke Foundation
^To qualify for this ALM, you must attend all 3 topics and complete a post conference activity that will be supplied onsite.
Please be informed that the above 3 modules can be undertaken as
a Category 2 activity.